Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_assertion type Assertion NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_head.
- NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_assertion description "[The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_provenance.
- NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_assertion evidence source_evidence_literature NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_provenance.
- NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_assertion SIO_000772 21908430 NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_provenance.
- NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_assertion wasDerivedFrom befree-20140225 NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_provenance.
- NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_assertion wasGeneratedBy ECO_0000203 NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_provenance.